Intravenous immunoglobulin (IVIG) is a cornerstone of autoimmune disease therapy, but its use is constrained by high costs and limited supply. A sialylated IgG1 Fc variant with enhanced affinity for the inhibitory Fcγ receptor FcγRIIB could offer an effective dose-sparing alternative to IVIG, potentially transforming treatments for autoimmune diseases.
- Sruthi Vijaya Retnakumar
- Jagadeesh Bayry
